Plant extract shows promise in treating pancreatic cancer

A natural extract derived from India's neem tree could potentially be used to treat pancreatic cancer, according to a new study in the journal Scientific Reports. Biomedical scientists at Texas Tech University Health Sciences Center El Paso (TTUHSC El Paso) tested nimbolide, a compound found in neem leaves, against pancreatic cancer in cell lines and mice. The results revealed that nimbolide can stop pancreatic cancer's growth and metastasis without harming normal, healthy cells.

"The promise nimbolide has shown is amazing, and the specificity of the treatment towards cancer cells over normal cells is very intriguing," says Rajkumar Lakshmanaswamy, Ph.D., an associate professor in TTUHSC El Paso's Center of Emphasis in Cancer.

Pancreatic cancer has the highest mortality rate of all cancers with 94% of patients dying within five years of diagnosis. The cancer grows quickly and there are currently no effective treatments available, underscoring the importance of finding new therapies.

In the study, Lakshmanaswamy and his lab observed that nimbolide was able to reduce the migration and invasion capabilities of pancreatic cancer cells by 70 percent; meaning the cancerous cells did not become aggressive and spread. And that's promising, the researchers say. In humans, this migration and invasion -- or metastasis -- of pancreatic cancer to other regions of the body is the chief cause of mortality.

Nimbolide treatments also induced cancer cell death, causing the size and number of pancreatic cancer cell colonies to drop by 80 percent. "Nimbolide seems to attack pancreatic cancer from all angles," Lakshmanaswamy says.

The TTUHSC El Paso researchers stress that one of the most important findings is that nimbolide did not harm healthy cells in both the in vitro and in vivo experiments.

Lead author and postdoctoral researcher Ramadevi Subramani, Ph.D., explains, "Many people in India actually eat neem and it doesn't have harmful side effects, which suggests that using nimbolide for pancreatic cancer will not cause adverse effects like chemotherapy and radiation typically do."

While the results are promising, Lakshmanaswamy says there's still a long way to go before nimbolide can be used to treat pancreatic cancer in humans.

The TTUHSC El Paso team plans to continue researching the anticancer mechanisms behind the plant extract. They'll also study various ways to administer nimbolide to maintain its potency against pancreatic cancer.

Additional TTUHSC El Paso collaborators who participated in the study were postdoctoral researchers Arunkumar Arumugam, Ph.D., Sushmita Nandy, Ph.D., and graduate students Fernando Camacho, Elizabeth Gonzalez, and Joshua Medel.

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]